Zobrazeno 1 - 10
of 36
pro vyhledávání: '"Andrei Breazna"'
Autor:
Jonathan L. Halperin, Andrei Breazna, Richard D. England, Judith Spahr, Jonas Oldgren, Maria Sudworth, Paulus Kirchhof, Sandra VanPelt Nguyen, Charles V. Pollack, Michael D. Ezekowitz, Nilo B. Cater
Publikováno v:
European Heart Journal
Aim The primary objective was to compare apixaban to heparin/vitamin K antagonist (VKA) in patients with atrial fibrillation (AF) and ≤48 h anticoagulation prior to randomization undergoing cardioversion. Methods One thousand five hundred patients
Autor:
Andrei Breazna, Franz H. Messerli, Chuan-Chuan Wun, Sripal Bangalore, David A. DeMicco, Investigators
Publikováno v:
Journal of the American College of Cardiology. 65:1539-1548
Background Studies demonstrate that lowering low-density lipoprotein cholesterol (LDL-C) using a statin is associated with significant reduction in cardiovascular events. Whether visit-to-visit variability in LDL-C levels affects cardiovascular outco
Autor:
Terje R. Pedersen, Michael Messig, John J.P. Kastelein, David D. Waters, Andrei Breazna, Jennifer E. Ho, David A. DeMicco, S. Matthijs Boekholdt
Publikováno v:
Journal of the American College of Cardiology. 61:148-152
Objectives The purpose of this study was to compare the incidence of new-onset diabetes (NOD) with cardiovascular (CV) event reduction at different levels of NOD risk. Background Statins reduce the number of CV events but increase the incidence of NO
Autor:
Andrew Neil, David A. DeMicco, Andrei Breazna, Helen M. Colhoun, Prakash Deedwania, Chuan-Chuan Wun, Graham A. Hitman, Terje R. Pedersen
Publikováno v:
European Heart Journal. 33:339-653
Autor:
Daniel J. Wilson, Jennifer E. Ho, David A. DeMicco, Allison J. Kean, Prakash Deedwania, David D. Waters, Chuan-Chuan Wun, Andrei Breazna, Kiran K. Khush
Publikováno v:
Ho, JE; Waters, DD; Kean, A; Wilson, DJ; Demicco, DA; Breazna, A; et al.(2012). Relation of improvement in estimated glomerular filtration rate with atorvastatin to reductions in hospitalizations for heart failure (from the Treating to New Targets [TNT] study). American Journal of Cardiology, 109(12), 1761-1766. doi: 10.1016/j.amjcard.2012.02.019. UCSF: Retrieved from: http://www.escholarship.org/uc/item/9wj4c5h7
Impaired kidney function often accompanies heart failure (HF) and is associated with a worse prognosis. This post hoc analysis of the Treating to New Targets (TNT) trial examined whether the observed decrease in HF hospitalizations with high- compare
Autor:
Samia Mora, David A. DeMicco, S. Matthijs Boekholdt, Andrei Breazna, John J.P. Kastelein, David D. Waters, Nanette K. Wenger, Prakash Deedwania, Benoit J. Arsenault
Publikováno v:
Circulation, 125(16), 1979-1987. Lippincott Williams and Wilkins
Background— Cardiovascular events occur among statin-treated patients, albeit at lower rates. Risk factors for this “residual risk” have not been studied comprehensively. We aimed to identify determinants of this risk above and beyond lipid-rel
Autor:
Benoit J. Arsenault, Jennifer E. Ho, Helen M. Colhoun, David A. DeMicco, Philip J. Barter, John J.P. Kastelein, Chuan-Chuan Wun, Andrei Breazna, David D. Waters
Publikováno v:
Journal of the American College of Cardiology. 57(14):1535-1545
Background Statin therapy might modestly increase the risk of new-onset T2DM. Methods We used a standard definition of diabetes and excluded patients with prevalent diabetes at baseline. We identified baseline predictors of new-onset T2DM and compare
Autor:
Prakash Deedwania, Nanette K. Wenger, David A. DeMicco, Andrei Breazna, John C. LaRosa, Heiner Greten, James Shepherd
Publikováno v:
The American Journal of Cardiology. 105:283-287
Analyses of randomized clinical trials are usually restricted to examination of time to first event. However, because many patients have multiple events, this approach precludes much potentially useful clinical and economic data. To assess the effect
Autor:
John C. LaRosa, Heiner Greten, Andrei Breazna, David A. DeMicco, Vera Bittner, David D. Waters, Scott M. Grundy, Colleen Johnson
Publikováno v:
The American Journal of Cardiology. 102:1312-1317
The Treating to New Targets (TNT) study demonstrated that intensive atorvastatin therapy to achieve low-density lipoprotein cholesterol concentrations well below recommended target levels provides an incremental clinical benefit in patients with stab
Autor:
Sanjiv J. Shah, John J.P. Kastelein, David A. DeMicco, Andrei Breazna, David D. Waters, Nanette K. Wenger, John C. LaRosa, James Shepherd, Philip J. Barter
Publikováno v:
Journal of the American College of Cardiology, 51(20), 1938-1943. Elsevier USA
OBJECTIVES: The aim of this post hoc analysis from the TNT (Treating to New Targets) trial is to determine whether patients with previous coronary artery bypass grafting (CABG) surgery achieved clinical benefit from intensive low-density lipoprotein